LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

UCB Pharma729 enrolled

Overview

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

729

Conditions

Rhinitis, Allergic, Perennial

Interventions

LevocetirizineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season. * A skin test for grass pollens positive: * Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6. Exclusion Criteria: * Have an associated asthma requiring corticosteroid treatment, * Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,

Outcomes

Primary Outcomes

Mean change from baseline of T4SS (four symptoms score) over two weeks of treatment

Secondary Outcomes

Clinical efficacy over the first and over two weeks of treatment measured by symptoms (scored and individuals); Onset of action; Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.